ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

BHVN Biohaven Ltd

40,69
0,79 (1,98%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Biohaven Ltd BHVN NYSE Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
0,79 1,98% 40,69 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
40,72 40,45 42,105 40,69 39,90
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
22/4/202422:05PRNUSBiohaven Announces Closing of Public Offering and Full..
17/4/202422:05PRNUSBiohaven Announces Proposed Public Offering of Common Shares
13/4/202415:00PRNUSBiohaven Showcases Innovative Neuroscience Portfolio with 20..
29/2/202422:16EDGAR2Form 8-K - Current report
29/2/202422:05PRNUSBiohaven Reports Fourth Quarter and Full Year 2023 Financial..
08/1/202413:30EDGAR2Form 8-K - Current report
08/1/202413:30PRNUSBiohaven Highlights Progress Across Innovative Portfolio and..
02/1/202413:00PRNUSBiohaven to Present at the 42nd Annual J.P. Morgan..
01/12/202322:30PRNUSBiohaven Presents Expanded EEG and Safety Data for BHV-7000..
14/11/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202322:05PRNUSBiohaven Reports Third Quarter 2023 Financial Results and..
16/10/202313:00PRNUSBiohaven Presents Preclinical Data Demonstrating..
05/10/202322:05EDGAR2Form 8-K - Current report
05/10/202322:05PRNUSBiohaven Announces Closing of Public Offering and Full..
04/10/202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/10/202305:56PRNUSBiohaven Announces Pricing of $225 Million Public Offering..
03/10/202303:41EDGAR2Form 8-K - Current report
02/10/202323:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/10/202323:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/10/202322:36PRNUSBIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
02/10/202322:01EDGAR2Form S-3ASR - Automatic shelf registration statement of..
27/9/202312:58EDGAR2Form 8-K - Current report
14/9/202313:00PRNUSBiohaven Completes Enrollment in Pivotal Phase 3 Study of..
05/9/202313:00PRNUSBiohaven Announces Positive Data from its Exploratory..
31/7/202323:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/7/202322:29EDGAR2Form 8-K - Current report
31/7/202315:31PRNUSBiohaven's Taldefgrobep Alfa Receives EU Orphan Drug..
31/7/202312:59PRNUSBiohaven Reports Second Quarter 2023 Financial Results and..
28/7/202322:35EDGAR2Form 8-K - Current report
27/7/202314:42DJNBiohaven Told That FDA Won't Review NDA Application for..
27/7/202313:00PRNUSBiohaven Provides Preliminary EEG Data Update for Kv7..
31/5/202313:00PRNUSBiohaven Provides Overview of Clinical Progress, Regulatory..
25/5/202323:00PRNUSBiohaven to Present R&D Day at Yale School of Management
12/5/202322:30PRNUSBiohaven Reports First Quarter 2023 Financial Results and..

Dernières Valeurs Consultées

Delayed Upgrade Clock